FDA approves weight loss drug Zepbound for sleep apnea - NBC News
Dec 20, 2024 · The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday.
FDA Approves First Medication for Obstructive Sleep Apnea
Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in...
FDA approves weight loss drug Zepbound to treat sleep apnea : …
Dec 21, 2024 · The Food and Drug Administration on Friday authorized the use of Zepbound, made by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea (OSA), a common...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – …
18 hours ago · The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults ...
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Dec 20, 2024 · The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep...
GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
MONDAY, Dec. 23, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the...
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
Dec 20, 2024 · The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea
Dec 23, 2024 · Zepbound is the first prescription drug approved for obstructive sleep apnea in individuals with obesity. It can help improve breathing during sleep and promotes weight loss. Clinical trials showed significant symptom improvement and weight reduction
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
Dec 21, 2024 · The AASM said patients on Zepbound should know that sustained weight loss is required for it to be effective against sleep apnea symptoms. The FDA approval comes amid growing discussion about the potential uses of weight …
News Release
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...